Polycystic Kidney Disease

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
References & Research
Research Papers
Connections
Featured Videos

1. Overview

Polycystic kidney disease (PKD) is an inherited disorder in which clusters of fluid-filled sacs, called cysts, develop in the kidneys and slowly grow over many years. As the cysts enlarge and multiply, they crowd out the healthy kidney tissue around them, so the kidneys become very large but work less and less well. PKD is the most common inherited kidney disease and one of the leading genetic causes of kidney failure worldwide. It is not something you catch or develop from your lifestyle — it is written into your genes from birth, even though the kidneys may look and feel normal for decades before any symptoms appear.

There are two main forms. The far more common one is autosomal dominant polycystic kidney disease (ADPKD), which usually shows up in adulthood and is the focus of this page. The much rarer and more severe form is autosomal recessive polycystic kidney disease (ARPKD), which typically affects babies and young children and is a separate, more aggressive disease. When people say "PKD" without qualification, they almost always mean ADPKD.

The most important thing to understand — and the most hopeful — is that PKD is no longer untreatable. For most of medical history, doctors could only watch the kidneys decline. Today there is a disease-modifying drug, tolvaptan, that genuinely slows cyst growth and the loss of kidney function, alongside well-proven everyday measures like tight blood-pressure control and good hydration. PKD is also a whole-body (systemic) disease, not just a kidney disease: it can affect the liver, the blood vessels in the brain, the heart valves, and the gut. Knowing this lets you and your care team watch for and manage problems before they become emergencies.

2. Epidemiology

ADPKD affects roughly 1 in 400 to 1 in 1,000 people, making it one of the most common life-threatening genetic disorders. Estimates vary because many people with mild disease are never formally diagnosed, but most experts cite a prevalence somewhere in that range. In the United States that translates to several hundred thousand affected individuals, and it accounts for an estimated 5 to 10% of all people receiving dialysis or living with a kidney transplant.

PKD affects all ethnic groups and both sexes roughly equally, although men tend to lose kidney function somewhat faster than women on average. Because the gene is passed from parent to child, the disease tends to run in families and often spans multiple generations — a grandparent, a parent, and several siblings or cousins may all be affected.

The rarer ARPKD is far less common, affecting roughly 1 in 20,000 births, and behaves very differently — it is often detected before or shortly after birth and frequently involves both severe kidney disease and liver scarring (fibrosis) in childhood.

3. Pathophysiology

To understand PKD, it helps to picture a healthy kidney as roughly a million tiny filtering tubes (nephrons) packed neatly together. In PKD, the cells lining these tubes carry a faulty instruction in a protein that sits on a hair-like sensor on the cell surface called the primary cilium. The proteins involved are polycystin-1 and polycystin-2. Normally these polycystins act like tiny antennae and traffic controllers, sensing fluid flow and keeping the tubes the right shape and size.

When the polycystins do not work properly, the lining cells become confused. Instead of forming straight, orderly tubes, small pockets bulge outward, pinch off, and fill with fluid. These become cysts. The cyst-lining cells keep dividing and keep pumping fluid into the cyst, so each cyst slowly expands — sometimes over decades. A hormone called vasopressin (the body's water-conserving hormone) drives much of this fluid secretion, which is exactly why hydration and the drug tolvaptan, both of which lower vasopressin's effect, can help slow the process.

As thousands of cysts enlarge, the kidneys swell to many times their normal size — sometimes each kidney grows from the size of a fist to the size of a football. The expanding cysts physically crush and replace the healthy filtering tissue, and they trigger inflammation and scarring (fibrosis) in between. The result is a slow, steady decline in kidney function over years. Importantly, only one bad gene copy is needed to cause ADPKD, but each individual cyst seems to start when the cells lining one tube lose their good copy too — which is why cysts appear gradually and unpredictably rather than all at once.

4. Etiology and Risk Factors

ADPKD is caused by a change (mutation) in one of two genes:

PKD1 (which makes polycystin-1) — the cause in about 78% of families. PKD1 disease tends to be more severe, with kidney failure often arriving earlier (commonly in a person's 50s).
PKD2 (which makes polycystin-2) — the cause in about 15% of families. PKD2 disease is generally milder, with kidney failure often delayed by a decade or more (commonly the 70s), and some people never reach failure at all.

A small number of families have mutations in other, rarer genes (such as GANAB or DNAJB11), and in some cases no mutation is found despite a clear clinical picture.

Inheritance — the part families most want to understand: "Autosomal dominant" means that if one parent has ADPKD, each child has a 50% chance of inheriting the gene, regardless of sex. It does not skip generations: a person who does not inherit the gene cannot pass it on. About 90% of cases come from an affected parent, so there is often a known family history of kidney disease, kidney failure, or dialysis. The remaining ~10% are "de novo" — the mutation arises new in that person, with no prior family history, which is why some people are the first in their family ever diagnosed.

The most powerful predictors of how fast PKD will progress are which gene is involved (PKD1 vs PKD2), the specific type of mutation, sex, and how large the kidneys already are. Lifestyle factors do not cause PKD, but uncontrolled high blood pressure, smoking, obesity, and high salt intake can speed up the decline.

5. Clinical Presentation

One of the most important facts about PKD is that it is often silent for many years. The kidneys can be quietly filling with cysts long before a person feels anything. When symptoms do appear, they usually start in early-to-mid adulthood (the 30s and 40s, though it varies widely).

High blood pressure is frequently the very first sign. An otherwise healthy young or middle-aged adult is found to have hypertension — sometimes years before any kidney symptoms — and this often turns out to be the earliest clue of ADPKD. This is why unexplained high blood pressure in a young person, especially with any family history, deserves a closer look.

Other common features include:

Pain in the side, back, or abdomen — from the sheer size of the enlarged kidneys, from bleeding into a cyst, or from a kidney stone. Pain can be a dull, constant ache or a sudden sharp episode.
Blood in the urine (hematuria) — sometimes visible, often from a cyst that has bled. It usually settles on its own but should always be reported.
Kidney stones — far more common in PKD than in the general population.
Recurrent urinary tract infections and cyst infections — a cyst that becomes infected can cause fever and localized pain and can be hard to treat because antibiotics struggle to penetrate the cyst.
A feeling of fullness or a visibly enlarging abdomen — as the kidneys grow large, some people can feel the masses or notice their waistline change.
Headaches — often related to high blood pressure, but a sudden, severe "worst headache of my life" is a medical emergency (see Complications).

It is worth saying plainly: many people with PKD live for years feeling completely well, and a diagnosis does not mean you are sick today. The symptoms above tend to come and go, and most are manageable. The single most useful thing a person with PKD can do early on is have their blood pressure checked and treated — that quiet, symptomless step protects the kidneys far more than reacting only when pain or other symptoms appear.

6. Diagnosis

PKD is usually diagnosed with a combination of family history, imaging, and sometimes genetic testing.

Ultrasound is the simplest, cheapest, and most common first test. Because the number of cysts that count as "abnormal" rises naturally with age, doctors use age-based criteria (often called the Pei or unified criteria) for people with a known family history. For example, in an at-risk adult aged 15–39, finding at least three cysts (one or both kidneys) strongly supports the diagnosis; older age groups require more cysts. Ultrasound is excellent for confirming established disease but can miss very early disease in young people.

MRI (and sometimes CT) is more sensitive and is especially valuable for measuring total kidney volume (TKV) — literally how large the kidneys have become. TKV is one of the best available predictors of how quickly the disease will progress, and it is used in the Mayo imaging classification to sort patients into risk classes (1A through 1E, with 1E declining fastest). This matters practically because it helps identify who is most likely to benefit from disease-modifying treatment.

Genetic testing can identify the exact PKD1, PKD2, or other mutation. It is most useful when the diagnosis is unclear, when imaging is ambiguous in a young person, when a potential living kidney donor from the family needs to be cleared, or when a couple is making reproductive decisions. A negative imaging result in a young at-risk person does not fully rule out PKD — genetic testing may be needed for certainty.

7. Treatment

Treatment of PKD has genuinely advanced. The goals are to slow the loss of kidney function, control symptoms, prevent complications, and prepare for kidney failure if and when it comes. Here is what the evidence supports.

Rigorous blood-pressure control

This is the foundation of every PKD treatment plan. High blood pressure both results from PKD and accelerates it, so controlling it protects the kidneys and the heart and brain. ACE inhibitors and ARBs (drugs that block the renin-angiotensin system, such as lisinopril or losartan) are the preferred medications. The large HALT-PKD trials showed that in younger patients with good kidney function, aiming for a lower blood-pressure target (around 110/75 mmHg) slowed the growth of the kidneys compared with a standard target, with acceptable safety. Adding a second renin-angiotensin drug did not provide extra benefit, so a single ACE inhibitor or ARB to a firm target is the usual approach.

High water intake and low salt

Because the hormone vasopressin drives cyst fluid secretion, drinking enough water to keep vasopressin low — and keeping salt intake down — is biologically sensible and is widely recommended as a safe, low-cost measure. Honest caveat: while the rationale is strong and high fluid intake is encouraged, large trials have not yet definitively proven that forcing extra water beyond normal thirst meaningfully slows progression for everyone, and it is not appropriate once the kidneys can no longer handle large fluid loads. Think of generous hydration and a low-salt diet as sound, supportive habits rather than a guaranteed cure.

Tolvaptan — the first disease-modifying drug

This is the landmark advance. Tolvaptan blocks vasopressin's effect on the kidney, directly reducing the signal that drives cyst growth. In the TEMPO 3:4 trial (earlier-stage disease) and the REPRISE trial (later-stage disease), tolvaptan slowed both the growth of total kidney volume and the decline in kidney function. It became the first drug approved (FDA, 2018) specifically to slow ADPKD progression in adults at risk of rapid progression.

It is important to be realistic about tolvaptan so expectations are accurate:

It slows, it does not stop or reverse, the disease. The benefit is meaningful over years, not a cure.
Aquaresis (huge urine output and thirst). Tolvaptan makes you produce a great deal of urine, so you must drink a lot of water and you will urinate frequently day and night. This is the single biggest reason people stop the drug — the lifestyle burden is real and should be discussed frankly before starting.
Liver-toxicity monitoring. Tolvaptan can cause liver injury, so monthly liver blood tests are required for the first 18 months and periodically after. The drug is dispensed through a monitored program for this reason.
It is best for people likely to progress rapidly (younger patients with declining function and rapidly enlarging kidneys), which is why imaging classification and genetics help select candidates.

Managing symptoms and complications

Pain: from simple measures and acetaminophen up to procedures that drain or shrink large cysts in severe cases. NSAIDs are generally avoided because they can harm the kidneys.
Kidney stones: hydration, dietary changes, and standard stone treatments.
Cyst infections: require antibiotics that penetrate cysts well (such as certain fluoroquinolones) and sometimes drainage.
Blood in the urine: usually managed with rest and hydration.

When the kidneys fail: dialysis and transplant

If PKD progresses to kidney failure, the treatments are dialysis or, ideally, a kidney transplant. There is genuinely good news here: people with PKD tend to do very well with transplantation — often better than patients with many other causes of kidney failure — because they are frequently otherwise healthier and the disease does not attack the transplanted kidney. The native (original) kidneys are usually left in place unless they are causing severe pain, repeated infections, or are simply too large to make room for the new kidney.

Family screening, genetic counseling, and reproductive options

Because PKD is inherited, an essential part of care is the family. Relatives can be offered screening and genetic counseling to understand their own risk. For couples who want to avoid passing on the gene, options include preimplantation genetic diagnosis (PGD) with IVF, in which embryos are tested and only unaffected ones are implanted. These are personal decisions, and counseling helps families weigh them without pressure.

Living with PKD day to day

Beyond the medical plan, a few practical habits make a real difference and help you stay in control:

Track your numbers. Keep a simple record of your blood pressure at home, and know your latest eGFR (a measure of kidney function from a blood test) and your kidney size from imaging. These let you and your doctor see the trend, not just a single snapshot.
Build a kidney-friendly plate. Lower salt, plenty of water, plant-forward meals, and moderation with red meat and processed foods all support both blood pressure and kidney health. As function declines, a dietitian can fine-tune protein, potassium, and phosphorus.
Protect your kidneys from avoidable hits. Check with a pharmacist before taking over-the-counter painkillers or supplements, mention your PKD before any scan that uses contrast dye, and treat urinary infections promptly.
Mind your mental health. A lifelong, inherited condition that may affect your children carries an emotional weight. Anxiety and grief are normal. Patient organizations (such as the PKD Foundation) offer community, education, and support — you do not have to carry it alone.
Plan ahead, calmly. If your kidneys are slowly declining, learning early about dialysis and especially transplant — including the possibility of a living donor before you ever need dialysis (a "preemptive" transplant) — gives you the best outcomes and the most choices.

8. Complications

PKD is a systemic disease, so its complications reach well beyond the kidneys.

Liver cysts

Cysts in the liver are very common in ADPKD and become more frequent with age, especially in women. The good news is that they are usually benign and rarely affect liver function — the liver keeps working normally even when it contains many cysts. In a minority of people, massive liver cysts cause discomfort, fullness, or pressure that may need treatment.

Intracranial (brain) aneurysms — the most serious to know about

People with ADPKD have a higher-than-average risk of brain aneurysms (sometimes called "berry" aneurysms) — weak, balloon-like bulges in brain arteries. Most never cause trouble, but if one ruptures it causes bleeding around the brain (subarachnoid hemorrhage), which is life-threatening. The risk is meaningfully higher if a close relative has had a brain aneurysm or bleed.

What this means for you, practically:

Screening with a non-invasive MRI of the brain (MR angiography) is generally recommended for people with a family history of aneurysm or brain hemorrhage, or those in certain high-risk jobs. Routine screening of everyone with PKD is not standard — it is a discussion to have with your doctor based on your family history.
Know the emergency sign: a sudden, severe headache — the "worst headache of your life," often described as a thunderclap, sometimes with a stiff neck, vision changes, or loss of consciousness — is a call-an-ambulance emergency. Do not wait it out.

Other systemic complications

Heart valve problems — mitral valve prolapse and other valve issues are more common; usually mild but worth knowing about.
Diverticulosis — pouches in the colon are more frequent, which can occasionally become inflamed (diverticulitis).
Hernias — abdominal and inguinal hernias occur more often, partly from the pressure of enlarged organs.
High blood pressure and heart disease — cardiovascular complications are the leading cause of death in PKD, which is another reason blood-pressure control is so central.

9. Prognosis

The honest, balanced picture: PKD is a progressive disease, but its course is highly variable, and outcomes have improved. Many people with ADPKD reach kidney failure in their 50s or 60s, but this is an average across a very wide range. Some people maintain good kidney function into old age and never need dialysis or transplant, while others progress faster.

What you can know about your own likely course depends on several predictors:

Which gene: PKD2 disease is generally milder and slower than PKD1.
Kidney size: the larger the total kidney volume for your age, the faster the expected decline — this is the basis of the Mayo imaging classification.
Risk scores: tools such as the PROPKD score combine genetic type, sex, and early events (like hypertension or blood in the urine before age 35) to estimate the risk of fast progression.
Blood pressure and lifestyle: well-controlled blood pressure and avoidance of smoking are associated with better outcomes.

The bottom line is hopeful but realistic: with modern care — tight blood-pressure control, healthy habits, and, for those who qualify, tolvaptan — the slope of decline can be made gentler, and when kidney failure does arrive, transplant offers an excellent quality of life.

10. Prevention

It is important to be honest: you cannot prevent the genetics of PKD. If you inherited the gene, you have the condition. So "prevention" here really means slowing progression and preventing complications — and these steps genuinely matter:

Control blood pressure aggressively — the single most important thing you can do, ideally with an ACE inhibitor or ARB to a firm target.
Stay well hydrated — generous water intake (unless your kidneys can no longer handle it) helps keep vasopressin low.
Eat a low-salt diet — less sodium helps blood pressure and may help the kidneys.
Maintain a healthy weight — obesity is linked to faster progression.
Avoid nephrotoxins — limit NSAID painkillers (ibuprofen, naproxen), be cautious with contrast dyes, and avoid unnecessary kidney-stressing supplements.
Do not smoke — smoking damages blood vessels and speeds kidney decline (and may raise aneurysm risk).
Moderate caffeine — caffeine can stimulate cyst-growth pathways in the lab, so very heavy intake is best avoided, though moderate amounts appear acceptable.
Keep your appointments — regular monitoring of kidney function, blood pressure, and imaging lets your team act early.

For families, the most powerful preventive action is screening relatives and seeking genetic counseling, so that high blood pressure and complications can be caught and treated as early as possible.

11. Recent Research and Advances

PKD research has moved from "no treatment" to "the first disease-modifying drug" within a generation, and the pipeline is active. Here is an honest snapshot of where things stand:

Tolvaptan in practice: Now that tolvaptan is approved and in real-world use, research focuses on identifying exactly who benefits most, managing the thirst and liver-monitoring burden, and improving long-term adherence.
Metabolic approaches: Because cyst-lining cells have an altered metabolism, trials are testing dietary strategies — including modest calorie restriction, ketogenic-style diets, and intermittent fasting — to see whether "starving" cysts of fuel slows growth. Early results are promising but not yet definitive; these should be tried only under medical supervision.
New drug targets: Researchers are studying somatostatin analogues (which have shown some benefit for liver and kidney cyst volume), mTOR-pathway and metabolic drugs, and agents aimed at the polycystin signaling and inflammation that drive cyst growth.
Better risk prediction: Refinements to imaging classification, genetic testing, and biomarkers aim to tell each patient sooner how fast their disease is likely to move, so treatment can be matched to need.
The longer horizon: gene-targeted and RNA-based therapies that address the underlying mutation are in early-stage science. They are exciting but not yet available, and patients should be cautious of any clinic offering "gene cures" outside legitimate trials.

The realistic takeaway: there is now a real treatment and a genuine research pipeline, which is a profound change from a decade ago — but disease-modifying options remain partial, and the everyday basics (blood pressure, hydration, healthy weight, no smoking) still do much of the heavy lifting.

12. References & Research

Historical Background

Although enlarged, cyst-filled kidneys had been described for centuries, the modern understanding of PKD began with the molecular genetics of the late twentieth century. The first gene, PKD1 (encoding polycystin-1), was identified by the European Polycystic Kidney Disease Consortium in 1994, and the second, PKD2 (encoding polycystin-2), by Mochizuki and colleagues in 1996. The discovery in the early 2000s that the polycystins reside on the primary cilium — the cell's tiny flow sensor — established the now-central "cilia paradigm" of cyst formation. Building on the recognition that vasopressin drives cyst growth, the large randomized HALT-PKD trials (2014) confirmed the value of tight blood-pressure control and renin-angiotensin blockade, and the TEMPO 3:4 (2012) and REPRISE (2017) trials demonstrated that the vasopressin-blocker tolvaptan slows disease — leading to its FDA approval in 2018 as the first drug to modify the course of ADPKD.

Key Research Papers

The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77(6):881–894.
Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272(5266):1339–1342.
Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nature Genetics. 2003;33(2):129–137.
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. The Lancet. 2007;369(9569):1287–1301.
Grantham JJ. Autosomal dominant polycystic kidney disease. New England Journal of Medicine. 2008;359(14):1477–1485.
Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. Journal of the American Society of Nephrology. 2009;20(1):205–212.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease (TEMPO 3:4). New England Journal of Medicine. 2012;367(25):2407–2418.
Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. Journal of the American Society of Nephrology. 2013;24(6):1006–1013.
Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease (HALT-PKD Study A). New England Journal of Medicine. 2014;371(24):2255–2266.
Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease (HALT-PKD Study B). New England Journal of Medicine. 2014;371(24):2267–2276.
Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease (Mayo classification). Journal of the American Society of Nephrology. 2015;26(1):160–172.
Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a KDIGO controversies conference. Kidney International. 2015;88(1):17–27.
Cornec-Le Gall E, Audrézet MP, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in ADPKD. Journal of the American Society of Nephrology. 2016;27(3):942–951.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease (REPRISE). New England Journal of Medicine. 2017;377(20):1930–1942.
Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nature Reviews Disease Primers. 2018;4(1):50.

Research Papers

The links below run live PubMed searches for current peer-reviewed literature on polycystic kidney disease and its management. Each opens the latest results in a new tab, so you can explore the evidence base for yourself.

Connections

Back to Table of Contents